Business challenge
The company had not yet focused on and explored the potential immuno-oncology (IO) aspects of the biology, or the implications of the IO story to the clinical development strategy, program value proposition, and company value-story until Lumanity proposed exploration of this to optimize the company’s clinical development, partnering, and funding strategies. The company also needed to identify the program’s value proposition in the rapidly evolving IO landscape.
Our approach
Through leveraging of our deep IO expertise, our biotech business model experience, and appreciation of large pharma needs and expectations from years of interaction around deals, we helped clarify key types of data and key partners, helped hone the messaging for the pitch/partner deck, and served as an ongoing sounding board for clinical and business strategy to the President of the US operations and head of BD, as well as for the CEO based in Europe. Also chaired several R&D days for analysts.
Valued outcome
Company went public on NASDAQ in 2020 and later underwent a major IO combination-driven partnering deal with a large pharma company around their lead program.
Overall, Lumanity supported the company over many projects over a five-year period, guiding the evolution of their thinking across multiple types of projects.
